United States Patent 11,344,536 (Ripretinib): What Is Claimed, What It Covers, and How Strong Is the Hypertension Dose-Adjustment Patent Estate
US Drug Patent 11,344,536 covers a specific dose-modification and treatment-management method for ripretinib when a patient develops Grade 3 hypertension during therapy for gastrointestinal stromal tumors (GIST). The claims are narrow in mechanism (withholding until blood pressure is controlled), narrow in decision rule (Grade 1 threshold), and narrow in dosing outcomes (150 mg vs 100 mg, with a specified daily 150 mg option in claim 1). The estate’s practical scope is tied to hypertension-management use of ripretinib dosing rather than to ripretinib itself, ripretinib compositions, or broad method-of-use across all indications.
What patents protect ripretinib dose adjustment for hypertension in GIST patients?
Immediate answer: US 11,344,536 is directed to a method of treating Grade 3 hypertension during ripretinib therapy for GIST by withholding ripretinib until blood pressure is controlled and then resuming at either 150 mg/day or 100 mg/day depending on whether post-control blood pressure is ≤ Grade 1 or > Grade 1.
What claim 1 requires (operational elements that define infringement)
Claim 1 is a method claim with multiple conjunctive limitations. A practicing clinician or protocol is within scope if each step is performed:
- Patient condition: “suffering from Grade 3 hypertension”
- Background therapy context: “while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors”
- Core management step: “withholding administration of ripretinib until the patient's blood pressure is controlled”
- Post-control dosing decision:
- if “less than or equal to Grade 1 blood pressure,” administer “150 mg daily ripretinib”
- if “more than Grade 1 blood pressure,” administer “100 mg daily ripretinib”
Claim 1 also ties to an initial dosing posture for the covered patient population: “150 mg daily or twice daily.” That language can matter in litigation because it implies the method is directed to patients who were administered ripretinib at that dose schedule before Grade 3 hypertension occurred.
Practical infringement shape
Because claim 1 is a step-by-step treatment-management method, the main infringement risk lies with:
- labeling-aligned treatment protocols that adopt the withholding-then-resume structure, and
- any clinical or investigator-driven regimen that uses a Grade 1 threshold to select between 150 mg/day and 100 mg/day after withholding.
What claims 2 and 3 add (species claims)
Claims 2 and 3 are narrower embodiments of claim 1:
- Claim 2: withholding until blood pressure is controlled, then if ≤ Grade 1 administer 150 mg daily
- Claim 3: withholding until blood pressure is controlled, then if > Grade 1 administer 100 mg daily
From an exclusivity/validity standpoint, claims 2 and 3 can be easier to map to specific branches of a protocol because they eliminate one dosing outcome each.
How broad are the claims of US 11,344,536 versus other ripretinib patents?
Immediate answer: The claims are narrower than general ripretinib dosing patents because they require a specific hypertension severity tier (Grade 3), a specific blood pressure control step (withholding until controlled), a specific threshold (≤ Grade 1 vs > Grade 1), and specific resulting doses (150 mg/day vs 100 mg/day). They are also indication-limited to GIST.
What the claims do not cover (scope boundaries that narrow the risk)
Based on the claim language provided, infringement is unlikely if key limitations are missing:
- No coverage for hypertension management that does not include “withholding” ripretinib.
- No coverage for dose modifications that do not use a Grade 1 threshold decision.
- No coverage for alternative dose outcomes outside 150 mg/day and 100 mg/day post-withholding (for example, 50 mg/day, intermittent dosing, or taper strategies not matching the claimed outcomes).
- No coverage for hypertension management in indications other than GIST, because the claim ties to “for treatment of gastrointestinal stromal tumors.”
- No coverage for formulations, crystalline forms, polymorphs, salts, or manufacturing methods, because the claims are method-of-treatment management claims.
Comparison to broader “dose reduction” method-of-use claims
In typical oncology IP landscapes, dose-reduction patents are often broad in:
- the adverse event category (not limited to hypertension or limited to “adverse events”),
- the grade thresholds (not limited to Grade 3 and Grade 1),
- the dose endpoints (not restricted to a single pair of doses),
- the indication (not restricted to GIST).
US 11,344,536 narrows on all four dimensions. That narrowing reduces the probability that a generic competitor or biosimilar-like entrant is automatically exposed whenever they adjust ripretinib dosing for safety.
When does US 11,344,536 lose exclusivity and when can generics launch?
Immediate answer: The user-provided material does not include the patent’s priority date, filing date, or term data. Without that, an exclusivity and launch timeline cannot be stated from the claim text alone.
What matters for timing in method-of-use patents
Even without dates, the practical timing question is governed by:
- whether US 11,344,536 is listed in the Orange Book for ripretinib for GIST (which determines Paragraph IV leverage for small-molecule generics), and
- whether any statutory exclusivity (regulatory) or pediatric extensions attach (rare for narrow method claims but possible in the broader estate).
Because those data are not provided, no launch window can be computed here.
What Orange Book status would determine generic entry risk for ripretinib if US 11,344,536 is listed?
Immediate answer: The claim language provided does not include Orange Book listing status, listing codes, or NDA/strength/dosage-form identifiers. Without those, the Orange Book status cannot be determined here.
Why Orange Book listing is decisive for method claims
For small-molecule drugs, Orange Book listing drives:
- whether a generic must file a Paragraph IV certification against the listed patents, and
- what “carve-out” design might be used (for example, avoiding the claimed method by using different dose-management logic).
If US 11,344,536 is listed only for certain strengths or dosing regimens, entry risk becomes conditional on whether the generic’s label and real-world use track the claimed branch points.
Is US 11,344,536 strong for litigation: novelty, definiteness, and claim mapping
Immediate answer: The claim structure is highly map-able to clinical protocol steps. Strength depends on whether prior art disclosed the same combination: Grade 3 hypertension management with ripretinib withholding until BP controlled, then restart at 150 mg/day if controlled to ≤ Grade 1 and at 100 mg/day if still > Grade 1, in GIST.
Claim construction pressure points
From a litigation standpoint, the highest-friction terms typically are:
-
“Grade 3 hypertension”
- Requires adoption of a grading system (commonly CTCAE in practice). Claim text does not define it. If a court construes “Grade 3” to align with CTCAE, then non-CTCAE measurement systems might be argued outside scope.
-
“blood pressure is controlled”
- “Controlled” is a functional term. Defendants often argue it requires a specific numeric threshold or duration, but claim language here does not specify.
-
“less than or equal to Grade 1 blood pressure” and “more than Grade 1”
- These are decision thresholds that create clear branching, improving infringement mapping. But they also create vulnerability if prior art used different thresholds.
-
“while being administered 150 mg ripretinib daily or twice daily”
- This clause constrains the context. If ripretinib is administered at a different starting regimen (e.g., different dose schedule) before Grade 3 hypertension develops, the method may not fall squarely under claim 1.
How claim 2 and 3 affect enforceability
Because claims 2 and 3 each select only one dosing outcome after BP control, they can strengthen enforceability if a protocol matches one branch. In many disputes, partial overlap can still sustain infringement of a species claim even if other embodiments are harder to prove.
What generic entry risks exist for competitors using different hypertension dose-reduction logic?
Immediate answer: If a competitor’s label, clinical protocol, or real-world standard of care deviates from the claimed sequence (withholding until BP controlled) and the claimed restart thresholds and doses, then the infringement path narrows substantially.
Design-around logic that tracks claim limitations
A generic or branded company seeking to avoid the literal method steps would need to alter one or more core limitations, such as:
- not withholding ripretinib, or withholding but restarting at a dose other than 150 mg/day vs 100 mg/day depending on a Grade 1 threshold; or
- using a different post-control decision rule than “≤ Grade 1” vs “> Grade 1”; or
- limiting dosing adjustments to different hypertension grades than Grade 3.
Because claims 2 and 3 are limited to one restart endpoint each, a design that avoids one endpoint can still fail if it matches the other. Risk reduction must be holistic.
How does US 11,344,536 compare with broader oncology adverse-event dose-adjustment claims?
Immediate answer: US 11,344,536 is closer to a “label-adjacent clinical algorithm” claim than to a “general dose reduction” claim. It is specific enough to be distinguishable from generic adverse-event patents but specific enough to be directly implicated if labels or guidelines adopted the same decision tree.
Typical patent estate patterns
In oncology, method patents often come in layers:
- baseline dosing,
- adverse-event interruption and resumption,
- severity thresholds,
- dose-level step-down schemes,
- and sometimes recurrence rules.
US 11,344,536 appears concentrated on one adverse-event category and one step-down logic. That concentration can provide enforceability leverage when a competitor follows the same grade-based restart algorithm, but it can also provide a clearer invalidity path if earlier art disclosed the same algorithm.
How many patents cover the same concept of ripretinib hypertension management?
Immediate answer: Not determinable from the provided information. A count requires a patent landscape search across the ripretinib family, assignees, continuations, and related jurisdictions. No such dataset is provided.
What patent litigation affects US 11,344,536 or ripretinib dose-adaptation claims?
Immediate answer: No litigation docket details were provided. Without named proceedings, parties, or filings, the litigation impact cannot be stated.
Key Takeaways
- US 11,344,536 is a narrow method-of-treatment claim that targets a Grade 3 hypertension management algorithm for ripretinib in GIST.
- Claim 1 requires: withholding ripretinib until BP is controlled, then restarting at 150 mg/day if the patient is ≤ Grade 1, or 100 mg/day if > Grade 1.
- Claims 2 and 3 narrow claim 1 into single-branch restart embodiments, improving mapping to specific protocols.
- The principal enforceability and design-around leverage comes from the grade thresholds (“Grade 3” and “Grade 1”) and the specific dose endpoints (150 mg/day vs 100 mg/day).
- Exclusivity, Orange Book status, and launch timing cannot be derived from the claim text alone.
FAQs
- Does US 11,344,536 cover interrupting ripretinib and restarting at 75 mg/day after Grade 3 hypertension?
- If a clinician manages hypertension using medication without withholding ripretinib, is infringement possible under the claim language?
- Does “blood pressure is controlled” require a specific numeric BP value or only a grading improvement to ≤ Grade 1?
- Can a competitor avoid risk by using a different restarting threshold than Grade 1 (for example, Grade 2)?
- Is the method claim limited to GIST patients only, or could other ripretinib indications fall within scope?
References
- United States Patent 11,344,536, claims 1-3 (provided in user prompt).
